Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Targeted Molecular and Immunohistochemical Analyses of Endometrial Clear Cell Carcinoma Show that POLE Mutations and DNA Mismatch Repair Protein Deficiencies Are Uncommon.

Baniak N, Fadare O, Köbel M, DeCoteau J, Parkash V, Hecht JL, Hanley KZ, Gwin K, Zheng W, Quick CM, Jarboe EA, Liang SX, Kinloch M.

Am J Surg Pathol. 2019 Apr;43(4):531-537. doi: 10.1097/PAS.0000000000001209.

PMID:
30585826
2.

Clear cell carcinoma of the endometrium: an immunohistochemical and molecular analysis of 45 cases.

Zannoni GF, Santoro A, Angelico G, Spadola S, Arciuolo D, Valente M, Inzani F, Pettinato A, Vatrano S, Fanfani F, Scambia G, Fraggetta F.

Hum Pathol. 2019 Jun 30;92:10-17. doi: 10.1016/j.humpath.2019.06.005. [Epub ahead of print]

PMID:
31269413
3.

The genetic landscape of endometrial clear cell carcinomas.

DeLair DF, Burke KA, Selenica P, Lim RS, Scott SN, Middha S, Mohanty AS, Cheng DT, Berger MF, Soslow RA, Weigelt B.

J Pathol. 2017 Oct;243(2):230-241. doi: 10.1002/path.4947. Epub 2017 Sep 5.

4.

Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.

Parra-Herran C, Lerner-Ellis J, Xu B, Khalouei S, Bassiouny D, Cesari M, Ismiil N, Nofech-Mozes S.

Mod Pathol. 2017 Dec;30(12):1748-1759. doi: 10.1038/modpathol.2017.81. Epub 2017 Aug 4.

5.

ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas.

Allo G, Bernardini MQ, Wu RC, Shih IeM, Kalloger S, Pollett A, Gilks CB, Clarke BA.

Mod Pathol. 2014 Feb;27(2):255-61. doi: 10.1038/modpathol.2013.144. Epub 2013 Jul 26.

6.

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN.

Cancer. 2017 Mar 1;123(5):802-813. doi: 10.1002/cncr.30496. Epub 2017 Jan 6.

7.

Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.

Hussein YR, Weigelt B, Levine DA, Schoolmeester JK, Dao LN, Balzer BL, Liles G, Karlan B, Köbel M, Lee CH, Soslow RA.

Mod Pathol. 2015 Apr;28(4):505-14. doi: 10.1038/modpathol.2014.143. Epub 2014 Nov 14.

8.

Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.

Espinosa I, De Leo A, D'Angelo E, Rosa-Rosa JM, Corominas M, Gonzalez A, Palacios J, Prat J.

Hum Pathol. 2018 Feb;72:100-106. doi: 10.1016/j.humpath.2017.11.006. Epub 2017 Nov 11.

PMID:
29133142
9.

Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.

Espinosa I, D'Angelo E, Corominas M, Gonzalez A, Prat J.

Hum Pathol. 2018 Jan;71:65-73. doi: 10.1016/j.humpath.2017.10.016. Epub 2017 Oct 24.

PMID:
29079180
10.

Does a p53 "Wild-type" Immunophenotype Exclude a Diagnosis of Endometrial Serous Carcinoma?

Fadare O, Roma AA, Parkash V, Zheng W, Walavalkar V.

Adv Anat Pathol. 2018 Jan;25(1):61-70. doi: 10.1097/PAP.0000000000000171. Review.

PMID:
28945609
11.

Precursors of endometrial clear cell carcinoma.

Fadare O, Liang SX, Ulukus EC, Chambers SK, Zheng W.

Am J Surg Pathol. 2006 Dec;30(12):1519-30.

PMID:
17122507
12.

[Clinical application of TCGA molecular classification in endometrial endometrioid carcinoma].

Du NN, Liu Y, Ren CX, Wang YX, Du J, Yang J, Liu CR.

Zhonghua Bing Li Xue Za Zhi. 2019 Aug 8;48(8):596-603. doi: 10.3760/cma.j.issn.0529-5807.2019.08.003. Chinese.

PMID:
31422589
13.

Targeted mutation analysis of endometrial clear cell carcinoma.

Hoang LN, McConechy MK, Meng B, McIntyre JB, Ewanowich C, Gilks CB, Huntsman DG, Köbel M, Lee CH.

Histopathology. 2015 Apr;66(5):664-74. doi: 10.1111/his.12581. Epub 2015 Jan 13.

PMID:
25308272
14.

Undifferentiated and Dedifferentiated Endometrial Carcinomas With POLE Exonuclease Domain Mutations Have a Favorable Prognosis.

Espinosa I, Lee CH, D'Angelo E, Palacios J, Prat J.

Am J Surg Pathol. 2017 Aug;41(8):1121-1128. doi: 10.1097/PAS.0000000000000873.

PMID:
28498284
15.

Should endometrial clear cell carcinoma be classified as Type II endometrial carcinoma?

Bae HS, Kim H, Young Kwon S, Kim KR, Song JY, Kim I.

Int J Gynecol Pathol. 2015 Jan;34(1):74-84. doi: 10.1097/PGP.0000000000000111.

PMID:
25473756
16.

PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.

Jin C, Hacking S, Liang S, Nasim M.

Int J Surg Pathol. 2019 Jul 16:1066896919862618. doi: 10.1177/1066896919862618. [Epub ahead of print]

PMID:
31311367
17.

POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.

Meng B, Hoang LN, McIntyre JB, Duggan MA, Nelson GS, Lee CH, Köbel M.

Gynecol Oncol. 2014 Jul;134(1):15-9. doi: 10.1016/j.ygyno.2014.05.006. Epub 2014 May 16.

PMID:
24844595
18.

Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations.

Haraldsdottir S, Hampel H, Tomsic J, Frankel WL, Pearlman R, de la Chapelle A, Pritchard CC.

Gastroenterology. 2014 Dec;147(6):1308-1316.e1. doi: 10.1053/j.gastro.2014.08.041. Epub 2014 Sep 3.

19.

Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.

Cohen SA, Turner EH, Beightol MB, Jacobson A, Gooley TA, Salipante SJ, Haraldsdottir S, Smith C, Scroggins S, Tait JF, Grady WM, Lin EH, Cohn DE, Goodfellow PJ, Arnold MW, de la Chapelle A, Pearlman R, Hampel H, Pritchard CC.

Gastroenterology. 2016 Sep;151(3):440-447.e1. doi: 10.1053/j.gastro.2016.06.004. Epub 2016 Jun 11.

20.

Practical guidance for mismatch repair-deficiency testing in endometrial cancer.

Stelloo E, Jansen AML, Osse EM, Nout RA, Creutzberg CL, Ruano D, Church DN, Morreau H, Smit VTHBM, van Wezel T, Bosse T.

Ann Oncol. 2017 Jan 1;28(1):96-102. doi: 10.1093/annonc/mdw542.

PMID:
27742654

Supplemental Content

Support Center